Nuvig Therapeutics Inc.

Nuvig Therapeutics Inc. is a biotechnology startup founded in 2021, with a focus on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company's slogan, "Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases," epitomizes its mission. Nuvig Therapeutics aims to bring about a paradigm shift in the treatment of such diseases by inducing natural mechanisms to restore immune homeostasis and rebalance immune function post-inflammation. This forward-looking approach underscores the potential to significantly enhance treatment options for patients in desperate need of effective solutions. In line with its vision, Nuvig Therapeutics secured a remarkable $47.00M Series A investment on 11 May 2022. The investors in this round, namely Novo Holdings, Digitalis Ventures, Mission BioCapital, and Bristol-Myers Squibb, serve as a testament to the growing confidence and support for the company's endeavors. With its headquarters based in the United States, Nuvig Therapeutics is strategically positioned within a hub of innovation and research in the biotechnology and healthcare sectors. By building a pipeline of novel immune therapeutics, Nuvig Therapeutics is poised to make significant contributions to the healthcare industry, addressing unmet medical needs and creating positive impact for individuals suffering from chronic inflammatory and autoimmune diseases. With its recent investment and strong backing from prominent investors, Nuvig Therapeutics is well-positioned to drive forward its innovative therapies and shape the future of disease management.